Spyre Therapeutics, Inc.
SYRENext catalyst
SPY002-072
Rheumatoid Arthritis
Get an email about SYRE's next catalysts
Track Spyre Therapeutics (SYRE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 3 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
4 upcoming, 1 past
SPY002-072 Phase 2 Est. Readout (SKYWAY-RD)
Primary completion for SPY002-072 trial (NCT07148414) in Rheumatoid Arthritis
SourceSYRE Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.79 | FQ end Sep/2026 | Call: tbd
SPY001 Phase 2 Est. Readout (SKYLINE-UC)
Estimated primary completion for SPY001 trial (NCT07012395) in Ulcerative Colitis. Topline data typically follows completion by weeks to months.
SourceSPY072 Phase 2 Est. Readout
Estimated primary completion for SPY072 trial (NCT07766005) in Hidradenitis Suppurativa (HS). Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
SPY002-072
Rheumatoid Arthritis
SPY001
Ulcerative Colitis
SPY072
Hidradenitis Suppurativa (HS)
SPY003
Ulcerative Colitis
bimekizumab
Hidradenitis Suppurativa (HS)
SPY002
Ulcerative Colitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SPY002-072 | Phase 2 | Rheumatoid Arthritis | - | - |
SPY001 | Phase 2 | Ulcerative Colitis | - | - |
SPY072 | Phase 2 | Hidradenitis Suppurativa (HS) | - | - |
SPY003 | Phase 2 | Ulcerative Colitis | - | - |
bimekizumab | Phase 2 | Hidradenitis Suppurativa (HS) | - | - |
SPY002 | Phase 2 | Ulcerative Colitis | - | - |
Frequently asked questions
What is in Spyre Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Spyre Therapeutics, Inc.'s (SYRE) pipeline across Phase 2. Its lead program is SPY001 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Spyre Therapeutics, Inc.'s next FDA catalyst?→
Spyre Therapeutics, Inc.'s (SYRE) next tracked catalyst is a Phase 2 readout expected October 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SYRE biotech catalysts?→
Add SYRE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Spyre Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.